Alivus Life Sciences Limited — PPTs, 14-05-2026: Investor Presentation

Alivus Life Sciences delivered a strong FY26! 💪 Revenue grew 6.9% YoY to ₹ 2,551.8 Cr, with EBITDA up 19.6% to ₹ 857.7 Cr. For Q4FY26, revenue was ₹ 689.1 Cr (+6.1% YoY).

The non-GPL business was a key driver, growing 13% YoY and now contributing 71% of total revenue. CDMO also saw a turnaround with 18% YoY growth. Growth momentum was healthy across India, Europe, Japan, and LATAM. 🚀

Future strategy focuses on robust capacity expansion at Solapur (greenfield) and existing sites, ramping up CDMO, and developing complex APIs including Oncology and Iron compounds. R&D investments are increasing, with a new R&D center underway.

Q4FY26 EBITDA margin improved to 34.4% (+230 bps YoY), with FY26 EBITDA margin at 33.6% (+360 bps YoY). FY26 EPS rose to ₹ 45.99. The company generated ₹ 259 Cr in free cash flow, holding ₹ 782.4 Cr in cash. 💰

Management expects high single-digit revenue growth for FY27, sustaining margins above 30% due to improving operating leverage and new product launches. #Alivus #PharmaStocks